VBK Stock Analysis: VERBIO Vereinigte BioEnergie | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 1.871m EUR | 12M Return: 157.3% | DE000A0JL9W6 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.11M
Qual. Beats: 0
Rev. Trend: -47.3%
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Verbio SE is a German bioenergy producer headquartered in Leipzig, founded in 2006 and listed on XETRA under the ticker VBK. The company manufactures and distributes biodiesel, bioethanol, biomethane, bio-based chemicals, animal feeds, fertilizers, and related products across Germany, Europe, North America, and other international markets. It operates through three segments - Biodiesel, Bioethanol/Biomethane, and Other - and serves end markets including fuels, pharmaceuticals, food, cosmetics, energy, and agriculture. The company was renamed from VERBIO Vereinigte BioEnergie AG to Verbio SE in December 2023.
As a GICS-classified Specialty Chemicals company within the Materials sector, Verbio uses agricultural feedstocks such as rapeseed, grain, and straw to produce renewable fuels and chemical precursors. Biodiesel and bioethanol are commonly blended with conventional fossil fuels to meet renewable energy mandates and lower transport-sector emissions, which underpins regulatory demand for producers in the European bioenergy value chain.
- Biodiesel margins track rapeseed feedstock spreads and EU blending quotas
- Biomethane segment revenue scales on European RNG capacity expansion
- Energy price volatility pressures bioethanol spread profitability
| Net Income: -75.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 8.60 > 1.0 |
| NWC/Revenue: 14.55% < 20% (prev 17.33%; Δ -2.79% < -1%) |
| CFO/TA 0.09 > 3% & CFO 121.8m > Net Income -75.0m |
| Net Debt (182.9m) to EBITDA (90.2m): 2.03 < 3 |
| Current Ratio: 1.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.7m) vs 12m ago -0.86% < -2% |
| Gross Margin: 7.03% > 18% (prev 14.87%; Δ -7.85% > 0.5%) |
| Asset Turnover: 132.3% > 50% (prev 107.4%; Δ 24.88% > 0%) |
| Interest Coverage Ratio: -2.45 > 6 (EBIT TTM -43.0m / Interest Expense TTM 17.5m) |
| A: 0.20 (Total Current Assets 540.8m - Total Current Liabilities 282.8m) / Total Assets 1.30b |
| B: 0.17 (Retained Earnings 220.0m / Total Assets 1.30b) |
| C: -0.03 (EBIT TTM -43.0m / Avg Total Assets 1.34b) |
| D: 1.46 (Book Value of Equity 768.8m / Total Liabilities 527.3m) |
| Altman-Z'' = 3.17 = A |
| DSRI: 0.91 (Receivables 112.0m/103.6m, Revenue 1.77b/1.49b) |
| GMI: 2.12 (GM 14.87% / 7.03%) |
| AQI: 0.22 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 1.19 (Revenue 1.77b / 1.49b) |
| TATA: -0.15 (NI -75.0m - CFO 121.8m) / TA 1.30b) |
| Beneish M = -2.43 (Cap -4..+1) = BBB |
As of August 07, 2026, the stock is trading at EUR 29.98 with a total of 79,821 shares traded. Over the past week, the price has changed by +2.11%, over one month by -2.22%, over three months by -17.82% and over the past year by +157.34%.
Current recommended Stop Loss: 26.90 (which is 10.3% or 1.8 ATR below the current price).
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
P/E Forward = 6.7385
P/S = 1.0502
P/B = 2.4201
P/EG = 5.8004
Revenue TTM = 1.77b EUR
EBIT TTM = -43.0m EUR
EBITDA TTM = 90.2m EUR
Long Term Debt = 175.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 28.6m EUR (from shortTermDebt, last quarter)
Debt = 259.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 32.1m
Net Debt = 182.9m EUR (calculated: Debt 259.6m - CCE 76.7m)
Enterprise Value = 2.05b EUR (1.87b + Debt 259.6m - CCE 76.7m)
Interest Coverage Ratio = -2.45 (Ebit TTM -43.0m / Interest Expense TTM 17.5m)
EV/FCF = 91.27x (Enterprise Value 2.05b / FCF TTM 22.5m)
FCF Yield = 1.10% (FCF TTM 22.5m / Enterprise Value 2.05b)
FCF Margin = 1.27% (FCF TTM 22.5m / Revenue TTM 1.77b)
Net Margin = -4.23% (Net Income TTM -75.0m / Revenue TTM 1.77b)
Gross Margin = 7.03% ((Revenue TTM 1.77b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 13.10% (prev 17.38%)
Tobins Q-Ratio = 1.58 (Enterprise Value 2.05b / Total Assets 1.30b)
Interest Expense / Debt = 6.75% (Interest Expense 17.5m / Debt 259.6m)
Taxrate = 46.75% (20.1m / 43.1m)
NOPAT = -22.9m (EBIT -43.0m * (1 - 46.75%)) [loss with tax shield]
Current Ratio = 1.91 (Total Current Assets 540.8m / Total Current Liabilities 282.8m)
Debt / Equity = 0.34 (Debt 259.6m / totalStockholderEquity, last quarter 768.8m)
Debt / EBITDA = 2.03 (Net Debt 182.9m / EBITDA 90.2m)
Debt / FCF = 8.13 (Net Debt 182.9m / FCF TTM 22.5m)
Total Stockholder Equity = 750.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.59% (Net Income -75.0m / Total Assets 1.30b)
RoE = -10.00% (Net Income TTM -75.0m / Total Stockholder Equity 750.3m)
RoCE = -4.64% (EBIT -43.0m / Capital Employed (Equity 750.3m + L.T.Debt 175.9m))
RoIC = -2.37% (negative operating profit) (NOPAT -22.9m / Invested Capital 965.1m)
WACC = 6.45% (E(1.87b)/V(2.13b) * Re(6.85%) + D(259.6m)/V(2.13b) * Rd(6.75%) * (1-Tc(0.47)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -29.34 | Cagr: -9.82%
[DCF] Terminal Value 75.44% ; FCFF base≈22.5m ; Y1≈22.6m ; Y5≈23.9m
[DCF] Fair Price = 2.97 (EV 372.2m - Net Debt 182.9m = Equity 189.3m / Shares 63.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.76 | # QB: 0
Revenue Correlation: -47.33 | Revenue CAGR: -4.54% | SUE: N/A | # QB: 0
EPS current Year (2026-06-30): EPS=0.76 | Chg30d=+46.73% | Revisions=+29% | GrowthEPS=+135.0% | GrowthRev=+13.6%
EPS next Year (2027-06-30): EPS=1.89 | Chg30d=+18.11% | Revisions=+50% | GrowthEPS=+149.3% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: +50% (up=6, down=1)